Physician

Richard S Demera, MD

According to 2025 Medicare claims, Richard Demera, MD (NPI: 1407816630) practices allergy/immunology in the Fresno, CA market, with the plurality of this provider's patient population coming from Fresno, CA. This provider's primary affiliated billing organization is RICHARD S. DEMERA, M.D. INC. (NPI: 1548457245; TIN: 260198485) and primary practice location at 93720-2993.

Demera's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,561 traditional Medicare patients, billed 49,788 HCPCS/CPT codes, and received $1,378,923 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,087 prescription claims across 609 beneficiaries totaling $1,190,840 in drug costs, led by Dupixent Syringe (Dupilumab). DME data shows 276 claims. Open Payments data shows 132 records totaling $12,241. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $247,385 to $1,378,923. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $243,109 to $1,190,840. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	474	11,545	$247,385
2016	523	24,992	$599,278
2017	601	23,716	$578,964
2018	655	32,734	$856,885
2019	1,002	42,166	$1,131,931
2020	1,228	50,920	$1,470,292
2021	1,362	57,658	$1,821,306
2022	1,472	57,715	$1,877,653
2023	1,501	58,741	$1,919,143
2024	1,561	49,788	$1,378,923

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	289	1,515	$243,109
2016	310	1,744	$282,895
2017	362	2,124	$419,258
2018	407	2,459	$591,641
2019	470	2,707	$688,573
2020	491	2,761	$864,162
2021	471	2,547	$825,234
2022	520	2,649	$877,328
2023	538	2,766	$1,074,085
2024	609	3,087	$1,190,840

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	38	263	$81,623
2016	34	272	$72,940
2017	48	319	$59,848
2018	70	338	$55,613
2019	38	304	$56,947
2020	54	362	$64,928
2021	79	468	$155,173
2022	65	424	$158,940
2023	66	372	$163,099
2024	24	276	$268,074

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	760	1,437	$97
92511	Exam of the nose and throat using an endoscope	402	464	$93
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	217	217	$76
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	1,100	1,906	$65
94010	Test to measure expiratory airflow and volume	293	473	$21

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Dupixent Syringe	Dupilumab	51	1,512	$205,833
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	196	8,038	$164,815
Hizentra	Immun Glob G(Igg)/Pro/Iga 0-50	24	665	$155,029
Xolair	Omalizumab	43	1,085	$131,413
Dupixent Pen	Dupilumab	28	784	$105,692

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	33	$189,675
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	12	$63,682
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	12	$7,912
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	12	28	$2,054
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	N/R	13	$1,822

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	132	$12,241	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Richard S. Demera, MD?

Tedicare shows public-source Medicare data for Richard S. Demera, MD (NPI 1407816630), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Richard S. Demera, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Richard S. Demera, MD?

Richard S. Demera, MD is linked to RICHARD S. DEMERA, M.D. INC. (billing NPI 1548457245) in the available physician profile data.

Does Richard S. Demera, MD have Open Payments data?

Richard S. Demera, MD has 132 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.